Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovelStem InternationalNSTM EV-to-EBIT is 0.88 as of Jul. 31, 2026. The stock has 2 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, NovelStem International ranks better than 97.14% on this metric.
NovelStem International (OTCPK:NSTM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
NovelStem International's Enterprise Value for the quarter that ended in Mar. 2026 was $2.33 Mil.
NovelStem International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International EV-to-EBIT Related Terms
NovelStem International EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NovelStem International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovelStem International EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NovelStem International's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where NovelStem International's EV-to-EBIT falls into.
NovelStem International's current Enterprise Value is $2.41 Mil.
NovelStem International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovelStem International (NSTM) has a EV-to-EBIT of 0.88 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NovelStem International and its competitors. According to the industry distribution chart, NovelStem International ranks #3 out of 105 companies in the Medical Diagnostics & Research industry, placing it in the top 2.9%.
Is NovelStem International's EV-to-EBIT too high?
NovelStem International's current EV-to-EBIT is 0.88. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.47. NovelStem International's value of 0.88 is 96.3% below this industry median. Based on the distribution chart, NovelStem International ranks #3 out of 105 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does NovelStem International's EV-to-EBIT compare to NOTVQ and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, NovelStem International ranks #3 out of 105 companies for EV-to-EBIT. This places NovelStem International in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 23.47. NovelStem International's value of 0.88 is 96.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.47, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovelStem International's current EV-to-EBIT of 0.88 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on NovelStem International and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovelStem International's current EV-to-EBIT is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovelStem International stock overvalued right now?
NovelStem International (NSTM) has a current EV-to-EBIT of 0.88. The current EV-to-EBIT is 0.88 and 96.3% below the Medical Diagnostics & Research industry median of 23.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For NovelStem International (NSTM), the current EV-to-EBIT is 0.88 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NovelStem International Corp is a holding company. Through its subsidiaries, the company is engaged in the development and commercialization of diagnostic technology that can predict patients' anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. The company also has an interest in a book publishing franchise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSTM has been successfully added to your 
